EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers

Yueming Zhu, Anupam Banerjee, Ping Xie, Andrey A Ivanov, Amad Uddin, Qiao Jiao, Junlong Jack Chi, Lidan Zeng, Ji Young Lee, Yifan Xue, Xinghua Lu, Massimo Cristofanilli und 9 weitere

Journal of Clinical Investigation · 15.05.2024 · 134 (10)

DOI: 10.1172/jci176390 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 26.03.2024. Verfasst von Yueming Zhu und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Chemical Biology and. Hauptthemen laut MEDLINE: 5'-Nucleotidase, Proteolysis, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIDDK NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite widespread utilization of immunotherapy, treating immune-cold tumors remains a challenge. Multiomic analyses and experimental validation identified the OTUD4/CD73 proteolytic axis as a promising target in treating immune-suppressive triple negative breast cancer (TNBC). Mechanistically, deubiquitylation of CD73 by OTUD4 counteracted its ubiquitylation by TRIM21, resulting in CD73 stabilization inhibiting tumor immune responses. We further demonstrated the importance of TGF-β signaling for orchestrating the OTUD4/CD73 proteolytic axis within tumor cells. Spatial transcriptomics profiling discovered spatially resolved features of interacting malignant and immune cells pertaining to expression levels of OTUD4 and CD73. In addition, ST80, a newly developed inhibitor, specifically disrupted proteolytic interaction between CD73 and OTUD4, leading to reinvigoration of cytotoxic CD8 + T cell activities. In preclinical models of TNBC, ST80 treatment sensitized refractory tumors to anti-PD-L1 therapy. Collectively, our findings uncover what we believe to be a novel strategy for targeting the immunosuppressive OTUD4/CD73 proteolytic axis in treating immune-suppressive breast cancers with the inhibitor ST80.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

5'-NucleotidaseProteolysisTriple Negative Breast NeoplasmsAnimalsFemaleHumansMiceCell Line, TumorGPI-Linked ProteinsNeoplasm ProteinsUbiquitinationUbiquitin-Specific Proteases

Stichwörter der Autor:innen

Cancer immunotherapyDrug screensOncologyTherapeutics

Substanzen

5'-NucleotidaseGPI-Linked ProteinsNeoplasm ProteinsOTUD4 protein, humanUbiquitin-Specific ProteasesNT5E protein, human

Autor:innen und Institutionen

  • Department of Pharmacology and Chemical Biology and.
  • Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Laufer Center for Physical and Quantitative Biology, School of Medicine, Stony Brook University, Stony Brook, New York, USA.
  • Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Emory Chemical Biology Discovery Center, Emory University School of Medicine, Emory University, Atlanta, Georgia, USA.
  • Driskill Graduate Program (DPG), Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

Förderung

  • NCI NIH HHS
  • NIDDK NIH HHS
  • NIGMS NIH HHS
  • NLM NIH HHS
  • NIH

Zitieren

APA

Zhu, Y., Banerjee, A., Xie, P., Ivanov, A. A., Uddin, A., Jiao, Q., Chi, J. J., Zeng, L., Lee, J. Y., Xue, Y., Lu, X., Cristofanilli, M., Gradishar, W. J., Henry, C. J., Gillespie, T. W., Bhave, M. A., Kalinsky, K., Fu, H., Bahar, I., …, & Wan, Y. (2024). Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers. Journal of Clinical Investigation, 134(10). https://doi.org/10.1172/jci176390

Vancouver

Zhu Y, Banerjee A, Xie P, Ivanov AA, Uddin A, Jiao Q, et al. Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers. Journal of Clinical Investigation. 2024;134(10). doi:10.1172/jci176390

BibTeX
@article{Zhu2024,
  author = {Zhu, Yueming and Banerjee, Anupam and Xie, Ping and Ivanov, Andrey A and Uddin, Amad and Jiao, Qiao and Chi, Junlong Jack and Zeng, Lidan and Lee, Ji Young and Xue, Yifan and Lu, Xinghua and Cristofanilli, Massimo and Gradishar, William J and Henry, Curtis J and Gillespie, Theresa W and Bhave, Manali Ajay and Kalinsky, Kevin and Fu, Haian and Bahar, Ivet and Zhang, Bin and Wan, Yong},
  title = {Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  volume = {134},
  number = {10},
  doi = {10.1172/jci176390}
}
Kostenlos starten →